Cynthia Turnbull

Cynthia Turnbull

Auto-generated profile, based on publicly available information

Cynthia Turnbull

Division of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University. Canberra, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2023 in Science Advances
Verified
Journal Article
Open access
CTCynthia Turnbull
Cynthia Turnbull
JBJosiah Bones
Josiah Bones
MSMaurice Stanley
Maurice Stanley
AMArti Medhavy
Arti Medhavy
HWHao Wang
Hao Wang
CVCarola G. Vinuesa
Carola G. Vinuesa
Autosomal dominant loss-of-function (LoF) variants in cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ) cause immune dysregulation with autoimmunity, immunodeficiency and lymphoproliferation (IDAIL). Incomplete penetrance and variable expressivity are characteristic of IDAIL caused by CTLA-4 haploinsufficiency (CTLA-4h), pointing to a role for genetic modifiers. Here, we describe an IDAIL proband carrying a maternally inherited pathogenic CTLA4 variant and a paternally inherited rare LoF missense variant in CLEC7A, which encodes for the β-glucan pattern recognition receptor DECTIN-1. The CLEC7A variant led to a loss of DECTIN-1 dimerization and surface expression. Notably, DECTIN-1 stimulation promoted human and mouse regulatory T cell (T reg ) differentiation from naïve αβ and γδ T cells, even in the absence of transforming growth factor–β. Consistent with DECTIN-1’s T reg -boosting ability, partial DECTIN-1 deficiency exacerbated the T reg defect conferred by CTL4-4h. DECTIN-1/ CLEC7A emerges as a modifier gene in CTLA-4h, increasing expressivity of CTLA4 variants and acting in functional epistasis with CTLA-4 to maintain immune homeostasis and tolerance.

28 February 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YZYaoyuan Zhang
Yaoyuan Zhang
RMrhiannon morris
rhiannon morris
GBGrant J. Brown
Grant J. Brown
ALAyla May D. Lorenzo
Ayla May D. Lorenzo
XMXiangpeng Meng
Xiangpeng Meng
JEJulia I. Ellyard
Julia I. Ellyard
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a clear genetic component. While most SLE patients carry rare gene variants in lupus risk genes, little is known about their contribution to disease pathogenesis. Amongst them, SH2B3—a negative regulator of cytokine and growth factor receptor signaling—harbors rare coding variants in over 5% of SLE patients. Here, we show that unlike the variant found exclusively in healthy controls, SH2B3 rare variants found in lupus patients are predominantly hypomorphic alleles, failing to suppress IFNGR signaling via JAK2-STAT1. The generation of two mouse lines carrying patients’ variants revealed that SH2B3 is important in limiting the number of immature and transitional B cells. Furthermore, hypomorphic SH2B3 was shown to impair the negative selection of immature/transitional self-reactive B cells and accelerate autoimmunity in sensitized mice, at least in part due to increased IL-4R signaling and BAFF-R expression. This work identifies a previously unappreciated role for SH2B3 in human B cell tolerance and lupus risk.

27 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RJRebecca A. Jaeger
Rebecca A. Jaeger
NRNadia A. Roberts
Nadia A. Roberts
CTCynthia M. Turnbull
Cynthia M. Turnbull
SSSandali Seneviratne
Sandali Seneviratne
RBRebecca L. Buckland
Rebecca L. Buckland
AEAnselm Enders
Anselm Enders
The decision of naïve T cells to differentiate into a specific Th cell subset after antigen encounter is a critical pivot point of the immune response and, when out of balance, can lead to autoimmunity, allergy or immunodeficiency. Th subset differentiation is determined by the expression of transcription factors including IRF4. We here describe a point mutation (IRF4 L116R ) in the DNA-binding domain of IRF4 leading to a dysregulation of CD4-T cell subsets and their functions. This point mutation does not alter overall protein expression. In sharp contrast to IRF4-null mice, neither the CD4/CD8 ratio nor T cell activation and memory is altered in naïve mice carrying the point mutation. However, IRF4 L116R T cells are reduced in their capability to differentiate into Th1, Th17 and Treg cells in a dose-dependent manner, contrasting with the findings in IRF4 KO T cells. Particularly striking is the loss of Th1-differentiation in T cells from homozygous I rf4 L116R/L116R mice while T cells completely lacking IRF4 show no reduction in Th1 differentiation. Furthermore, despite maintained ability to generate Th17 cells, expression of the IRF4 L116R variant protects mice against disease development in the Th17 cell-dependent EAE mouse model of neuroinflammation. This contrasts with IRF4 knock-out mice, where expression of one wild-type allele of IRF4 is sufficient for full disease development. Together our results show that the L116R point mutation in IRF4 can selectively alter the differentiation and function of some CD4 T cell subsets and suggest that the L116R mutation is not a classical loss- or gain-of-function variant.